Written question asked by Andrew Gwynne (Labour) on Tuesday, 10 January 2017, in the House of Commons. It was due for an answer on Thursday, 12 January 2017. It was answered by Baroness Blackwood of North Oxford (Conservative) on Wednesday, 18 January 2017 on behalf of the Department of Health.
Breast Cancer: Drugs
- Question
-
To ask the Secretary of State for Health, what discussions his Department has had with (a) the National Institute for Health and Care Excellence and (b) Roche on draft guidance on Kadcyla (trastuzumab emtansine) during the consultation period.
- Answer
-
Neither Ministers nor officials have had any such discussions with the National Institute for Health and Care Excellence (NICE). Officials have had contact with Roche about its patient access scheme proposals for trastuzumab emtansine since the consultation on NICE’s draft guidance opened on 20 December 2016.
Secondary information
- Type
- Written question
- Reference
- 59317
- Session
- 2016-17
- Subjects
- Breast cancer Drugs National Institute for Health and Care Excellence Roche
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2017-01-21 17:35:20 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/59317
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/59317
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/59317